Dear reader, in only a few years, an American startup evolved from a simple platform selling hair-loss treatments into one of ...

Hims & Hers Health (NYSE: HIMS), a telehealth platform, has recently announced its Q1 financial results, showing notable year-over-year growth. The company reported adjusted earnings per share of ...

HIMS is set to report Q3 results with EPS estimated to be 9 cents and revenues of $583.7 million. HIMS' new hormonal health offerings and AI enhancements aim to expand reach and lift user engagement ...

HIMS is set to report Q2 results on Aug. 4, with EPS estimated at $0.18 and revenue at $551.8 million. Subscriber growth, better onboarding and GLP-1 uptake drove higher online revenue per user in Q1.

Hims & Hers stock (NYSE: HIMS) increased by 16% yesterday following its announcement about expanding into the treatment of menopause and perimenopause—a strategic shift indicating that the company is ...

Hims is a telehealth company offering discreet virtual consultations and prescription delivery for men's health concerns. Hims' hair loss program uses FDA-approved treatments like finasteride and ...